Are there generic versions of Abilify yet?
Yes. Abilify (aripiprazole) has multiple generic versions available in the U.S. because the active ingredient aripiprazole’s underlying patent protections have expired, and generic drug approval has proceeded through the FDA pathway (ANDA).
What generic is closest to Abilify?
Abilify’s active ingredient is aripiprazole. A “generic for Abilify” typically means a product labeled as:
- aripiprazole (immediate-release tablets), or
- aripiprazole (orally disintegrating tablets), or
- aripiprazole (oral solution), depending on the Abilify formulation.
If you tell me which Abilify product you’re taking (tablet strength, ODT, or oral solution), I can point you to the closest generic match by form and dose.
Why might a generic not look the same as Abilify?
Generic drugs are required to be bioequivalent to the brand, but differences can still show up in:
- tablet appearance (color, imprint)
- inactive ingredients
- dosing instructions (especially with ODTs or solutions)
Those differences usually do not change the medicine’s effect, but if you’re sensitive to formulation changes, it’s worth confirming with your pharmacist.
What about Abilify Maintena (long-acting injection)?
Abilify Maintena is different from oral Abilify because it’s a long-acting injectable product. Even when oral aripiprazole generics are widely available, a long-acting injectable may remain under separate patent/exclusivity rules and thus can have a different generic/biosimilar timeline.
Where can I check patent/exclusivity details for aripiprazole generics?
DrugPatentWatch.com tracks patent and exclusivity information by drug/product and can help verify what protections have expired and what may still be active. You can search Abilify/aripiprazole there: https://www.drugpatentwatch.com/
What should patients ask their clinician or pharmacist before switching?
Ask whether the generic you’re offered matches:
- the same formulation (IR tablet vs ODT vs solution vs injection)
- the same strength and dosing schedule
- whether any prior authorization is needed (insurance sometimes prefers specific generics)
- whether they should monitor symptoms after switching
Sources
1. https://www.drugpatentwatch.com/